Published in J Alzheimers Dis on January 01, 2010
BACE2 expression increases in human neurodegenerative disease. Am J Pathol (2011) 0.95
A canine model of human aging and Alzheimer's disease. Biochim Biophys Acta (2013) 0.93
Choroid plexus dysfunction impairs beta-amyloid clearance in a triple transgenic mouse model of Alzheimer's disease. Front Cell Neurosci (2015) 0.90
Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease. Ann Neurol (2012) 0.89
Temporal course of cerebrospinal fluid dynamics and amyloid accumulation in the aging rat brain from three to thirty months. Fluids Barriers CNS (2012) 0.87
Antioxidants in Down syndrome. Biochim Biophys Acta (2011) 0.85
Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression. J Alzheimers Dis (2012) 0.83
Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges. Front Pharmacol (2014) 0.82
A combination cocktail improves spatial attention in a canine model of human aging and Alzheimer's disease. J Alzheimers Dis (2012) 0.81
Proteotoxicity and cardiac dysfunction. Circ Res (2015) 0.81
Characterization of Amyloid-β Deposits in Bovine Brains. J Alzheimers Dis (2016) 0.78
Young to Middle-Aged Dogs with High Amyloid-β Levels in Cerebrospinal Fluid are Impaired on Learning in Standard Cognition tests. J Alzheimers Dis (2016) 0.75
Alzheimer's disease biomarkers in animal models: closing the translational gap. Am J Neurodegener Dis (2013) 0.75
Aβ vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, Aβ, and microhemorrhages. Neurobiol Aging (2016) 0.75
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51
Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun (1984) 8.14
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci (2001) 6.32
Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J (1985) 6.24
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A (2002) 5.46
An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science (1994) 5.10
Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem (2004) 4.33
The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2002) 4.27
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A (2009) 3.86
Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science (1987) 3.23
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 3.15
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci (2006) 2.47
Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol (2008) 2.44
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci (2005) 2.17
Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis (2009) 2.12
A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet (2006) 2.01
Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. J Biol Chem (1994) 1.88
Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci (2007) 1.85
Neuritic (senile) plaques and filamentous changes in aged rhesus monkeys. J Neuropathol Exp Neurol (1973) 1.85
Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci (2002) 1.66
Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol (2006) 1.64
Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res Mol Brain Res (1991) 1.44
FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Neurobiol Aging (2002) 1.44
Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis (2007) 1.40
Mice as models: transgenic approaches and Alzheimer's disease. J Alzheimers Dis (2006) 1.32
Tauopathy with paired helical filaments in an aged chimpanzee. J Comp Neurol (2008) 1.27
Amyloid precursor protein in aged nonhuman primates. Proc Natl Acad Sci U S A (1991) 1.19
PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol Aging (2009) 1.15
A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci (2008) 1.15
Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol Aging (1999) 1.13
Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem (1996) 1.11
Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging (2000) 1.10
Beta-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol Aging (1994) 1.03
Senile plaques in aged squirrel monkeys. Neurobiol Aging (1987) 0.96
Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. Neurobiol Aging (1996) 0.95
The progression of beta-amyloid deposition in the frontal cortex of the aged canine. Brain Res (1997) 0.93
Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol (2001) 0.84
Amyloid beta 1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs. Biochem J (1996) 0.82
Filamentous tau pathology in nerve cells, astrocytes, and oligodendrocytes of aged baboons. J Neuropathol Exp Neurol (2000) 0.81
Molecular biology of brain aging and neurodegenerative disorders. Acta Neurobiol Exp (Wars) (1996) 0.78
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem (2004) 5.14
Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem (2004) 4.33
Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem (2005) 4.23
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener (2007) 4.15
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem (2007) 3.42
Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem (2002) 3.37
Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci (2005) 3.27
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A (2004) 2.32
Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology (2006) 2.27
Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis (2009) 2.12
Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. J Biol Chem (2006) 2.09
Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem (2008) 2.04
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci (2003) 1.87
Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79
Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep (2012) 1.77
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature (2012) 1.77
Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol (2006) 1.77
Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol (2006) 1.72
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 1.70
Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener (2011) 1.67
Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol (2006) 1.64
Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem (2008) 1.56
Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.55
Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci (2009) 1.54
Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem (2011) 1.53
Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol (2009) 1.53
Preparation and characterization of neurotoxic tau oligomers. Biochemistry (2010) 1.53
Juvenile traumatic brain injury evolves into a chronic brain disorder: behavioral and histological changes over 6months. Exp Neurol (2013) 1.49
Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl Acad Sci U S A (2005) 1.49
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab (2006) 1.47
Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry (2007) 1.44
NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci (2005) 1.44
Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest (2006) 1.43
Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis (2007) 1.40
Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates. Proc Natl Acad Sci U S A (2012) 1.39
Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation (2008) 1.38
Autophagy defends pancreatic β cells from human islet amyloid polypeptide-induced toxicity. J Clin Invest (2014) 1.37
A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci (2009) 1.36
The myosin converter domain modulates muscle performance. Nat Cell Biol (2002) 1.36
Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. Am J Pathol (2009) 1.33
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci (2014) 1.28
ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem (2006) 1.28
Androgen cell signaling pathways involved in neuroprotective actions. Horm Behav (2007) 1.28
Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol Aging (2007) 1.28
Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci (2012) 1.27
Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem (2011) 1.24
CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice. J Neurosci (2011) 1.22
Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci (2009) 1.18
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis (2009) 1.17
Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res (2006) 1.17
Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. J Neurosci Res (2010) 1.17
Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res (2005) 1.16
BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem (2009) 1.16
A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci (2008) 1.15
Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell (2008) 1.15
Exercise reverses preamyloid oligomer and prolongs survival in alphaB-crystallin-based desmin-related cardiomyopathy. Proc Natl Acad Sci U S A (2007) 1.12
Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest (2013) 1.12
Pore-forming proteins share structural and functional homology with amyloid oligomers. Neuromolecular Med (2007) 1.12
Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A (2002) 1.11
Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging (2006) 1.10
Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J Neurosci Res (2009) 1.08
Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther (2009) 1.07
Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate. PLoS One (2009) 1.07
Amyloid precursor protein (APP) regulates synaptic structure and function. Mol Cell Neurosci (2012) 1.06
The species-specific egg receptor for sea urchin sperm adhesion is EBR1,a novel ADAMTS protein. Genes Dev (2003) 1.05
Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci (2010) 1.04
Formation and propagation of tau oligomeric seeds. Front Neurol (2013) 1.04
Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation (2005) 1.03